Showing results (1-10 of 291) with videos related to
Sort By:
Pageof 30
Current Opinion in Lipidology|April 19, 2015
Role of PCSK9 beyond liver involvementBertrand Cariou, Karim Si-Tayeb, Cédric Le MayMedecine Sciences : M/S|October 14, 2021
[Hepatic organoids: What are the challenges?]Eléanor Luce, Antonietta Messina, Amandine Caillaud, et al.Bulletin De L'Academie Nationale De Medecine|July 21, 2012
[The liver]Dominique Franco, Karim Si-TayebDisease Models & Mechanisms|November 21, 2015
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemiaKarim Si-Tayeb, Salam Idriss, Benoite Champon, et al.Developmental Cell|February 18, 2010
Organogenesis and development of the liverKarim Si-Tayeb, Frédéric P Lemaigre, Stephen A DuncanLa Revue Du Praticien|January 12, 2016
[A YOUNG MAN WHOSE LDL-CHOLESTEROL IS GREATER THAN 1.9 G/L]Bertrand CariouDiabetes, Obesity & Metabolism|January 11, 2022
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatmentBertrand CariouBMC Developmental Biology|June 8, 2010
Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratumMasato Nagaoka, Karim Si-Tayeb, Toshihiro Akaike, et al.Bioengineering & Translational Medicine|July 22, 2024
Human induced pluripotent stem cells-derived liver organoids grown on a Biomimesys® hyaluronic acid-based hydroscaffold as a new model for studying human lipoprotein metabolismMeryl Roudaut, Amandine Caillaud, Zied Souguir, et al.Diabetes, Obesity & Metabolism|April 20, 2019
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemiaWieneke Dijk, Bertrand CariouPageof 30